Poor-quality drugs and global trade: A pilot study

American Journal of Health Economics

Volumn 2, Issue 3, 2016, Pages 373-398

  Bate, Roger ^a   Jin, Ginger Zhe ^b   Mathur, Aparna ^a   Attaran, Amir ^c  

^a AMERICAN ENTERPRISE INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c RYERSON UNIVERSITY   (Canada)

Author keywords

Africa; India; International trade; Prescription drug; Quality

Indexed keywords

EID: 85040677482     PISSN: 23323493     EISSN: 23323507     Source Type: Journal    
DOI: 10.1162/ajhe_a_00049     Document Type: Article

References (45)

1. Akunyili, Dora. 2005. “Counterfeit and Substandard Drugs, Nigeria’s Experience: Implications, Challenges, Actions and Recommendations.” Speech at the World Bank. Accessed August 1, 2014. http://www.siteresources.worldbank.org.
2. Arora, Ashish, Lee Branstetter, and Chirantan Chatterjee. 2008. “Strong Medicine: Patent Reform and the Emergence of a Research-Driven Pharmaceutical Industry in India.” Working paper.
3. Attaran, Amir, Donna Barry, Shamnad Basheer, Roger Bate, David Benton, James Chauvin, Laurie Garrett, et al. 2012. “How to Achieve International Action on Falsified and Substandard Medicines.” British Medical Journal 345:e7381.
4. Baldwin, Richard, and James Harrigan. 2011. “Zeros, Quality, and Space: Trade Theory and Trade Evidence.” American Journal: Microeconomics 3 (2): 60-88.
5. Bate, Roger. 2012. Phake: The Deadly World of Falsified and Substandard Medicines. Washington, DC: American Enterprise Institute Press.
6. Bate, Roger, Paul Jensen, Kimberly Hess, Lorraine Mooney, and Julissa Milligan. 2013. “Substandard and Falsified Anti-tuberculosis Drugs: A Preliminary Field Analysis.” International Journal of Tuberculosis and Lung Disease 17 (3): 308-11.
7. Bate, Roger, Ginger Zhe Jin, and Aparna Mathur. 2011. “Does Price Reveal Poor-Quality Drugs? Evidence from 17 Countries.” Journal of Health Economics 30 (6): 1150-63.
8. Bate, Roger. 2015. “Falsified or Substandard? Assessing Price and Non-Price Signals of Drug Quality.” Journal of Economics and Management Strategy 24 (4): 687-711.
9. Bate, Roger, Lorraine Mooney, Emily Putze, Alexandra McPherson, and Sarah Naoshy. 2010. “Drug Registration: A Necessary but Not Sufficient Condition for Good Quality Drugs: A Preliminary Analysis of Twelve Countries.” Africa Fighting Malaria working paper. Accessed September 5, 2014. http://www.fightingmalaria.org/files/document/1/70/57362998355070ed9865bb.pdf.
10. Bennett, Daniel, and Wesley Yin. 2014. “The Market for High Quality Medicine: Retail Chain Entry and Drug Quality in India.” Working paper. Accessed June 22, 2015. http://luskin.ucla.edu/wes-yin.
11. Binagwaho, Agnes, Roger Bate, Micahel Gasana, Corine Karema, Yves Mucyo, John Patrick Mwesigye, Floribert Biziyaremye, et al. 2013. “Substandard and Falsified Medicines: A View from Rwanda.” PLOS Medicine 10 (7): e1001476.
12. Cameron, Alexandra, Margaret Ewen, Dennis Ross-Degnan, D. Ball, and Richard Laing. 2008. “Medicine Prices, Availability, and Affordability in 36 Developing and Middle-Income Countries: A Secondary Analysis.” The Lancet 373 (9559): 240-49.
13. CDSCO (Central Drug Standard Control Organization, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India). 2009. “Report on Countrywide Survey for Spurious Drugs.” Accessed December 16, 2014. http://www.cdsco.nic.in/writereaddata/REPORTBOOK13-7-10.pdf.
14. Chaudhuri, Shubham, Pinelopi Goldberg, and Panle Gia. 2006. “Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India.” American Economic Review 96 (5): 1477-1513.
15. Cockburn, Iain, Jean Lanjouw, and Mark Schankerman. 2016. “Patents and Global Diffusion of New Drugs.” American Economic Review 106 (1): 136-64.
16. Crozet, Matthieu, Keith Head, and Thierry Mayer. 2012. “Quality Sorting and Trade: Firm-Level Evidence for French Wine.” Review of Economic Studies 79:609-44.
17. Duggan, Mark, and Aparajita Goyal. 2012. “Pharmaceutical Patents and Prices: A Preliminary Empirical Assessment Using Data from India.” World Bank Policy Research Working Paper No. 6063.
18. Eban, Katherine. 2013. “Dirty Medicine.” Fortune. Accessed August 27, 2014. http://fortune.com/2013/05/15/dirty-medicine/.
19. HAI (Health Action International). 2010. “Being Sick and Needing Medicines Is a Costly Misfortune in Many Countries -A One Day Snapshot of a Medicine’s Price across 93 Countries.” http://www.haiweb.org/medicineprices/05012010/Globalbriefingnote.pdf.
20. Hallak, Juan Carlos. 2006. “Product Quality and the Direction of Trade.” Journal of International Economics 68 (1): 238-65.
21. Hummels, David, and Peter J. Klenow. 2005. “The Variety and Quality of a Nation’s Exports.” American Economic Review 95 (3): 704-23.
22. Hummels, David, and Alexandre Skiba. 2004. “Shipping the Good Apples Out? An Empirical Confirmation of the Alchian-Allen Conjecture.” Journal of Political Economy 112 (6): 1384-1402.
23. IMF (International Monetary Fund). 2009-12. “World Economic Outlook Database.” Accessed August 27, 2014. http://www.imf.org/en/Data.
24. IOM (Institute of Medicine). 2013. Countering the Problem of Falsified and Substandard Drugs. Edited by Gillian J. Buckley and Lawrence O. Gostin. Washington, DC: National Academies Press.
25. Jähnke, Richard W. O., Gabrielle Küsters, and Klaus Fleischer. 2001. “Low-Cost Quality Assurance of Medicines Using the GPHF-Minilab®.” Drug Information Journal 35 (3): 941-45.
26. Johnson, Robert C. 2012. “Trade and Prices with Heterogeneous Firms.” Journal of International Economics 86 (1): 43-56.
27. Kaale, Eliangiringa, Peter Risha, and Thomas Layloff. 2011. “TLC for Pharmaceutical Analysis in Resource Limited Countries.” Journal of Chromatography A 1218 (19): 2732-36.
28. Kaur, Harparkash, Catherine Goodman, Eloise Thompson, Kathy-Anne Thompson, Irene Masanja, S. Patrick Kachur, and Salim Abdulla. 2008. “A Nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania.” PLoS ONE 3 (10): e3403.
29. Khandelwal, A. 2010. “The Long and Short (of) Quality Ladders.” Review of Economic Studies 77 (4): 1450-76.
30. KPMG. 2006. “The Indian Pharmaceutical Industry: Collaboration for Growth.” Accessed June 16, 2014. https://www.in.kpmg.com/pdf/Indian%20Pharma%20Outlook.pdf.
31. Kyle, Margaret, and Anita McGahan. 2012. “Investments in Pharmaceuticals Before and After TRIPS.” Review of Economics and Statistics 94 (4): 1157-72.
32. Kyle, Margaret, and Yi Qian. 2013. “Intellectual Property Rights and Access to Innovation: Evidence from TRIPS.” Working paper.
33. Price water house Coopers. 2009. “Which Are the Largest City Economies in the World and How Might This Change by 2025?” PricewaterhouseCoopers UK Economic Outlook. Accessed August 2014. http://pwc.blogs.com/files/global-city-gdp-rankings-2008-2025.pdf.
34. Raufu, Abiodun. 2003. “India Agrees to Help Nigeria Tackle the Import of Fake Drugs.” British Medical Journal 326 (7401): 1234.
35. Schott, Peter K. 2004. “Across-Product versus Within-Product Specialization in International Trade.” Quarterly Journal of Economics 119 (2): 647-78.
36. Seiter, Andreas. 2010. “A Practical Approach to Pharmaceutical Policy.” World Bank. https://openknowledge.worldbank.org/handle/10986/2468.
37. Sharma, Prabodh, Sanjeev Kumar, Rakesh Pahwa, and Archana Sharma. 2008. “Opportunities for Generic Drugs in India.” Internet Journal of Third World Medicine 8:1.
38. Stanton, Cynthia, Alissa Koski, Patience Cofie, Ellie Mirzabagi, Breanna L. Grady, and Steve Brooke. 2012. “Uterotonic Drug Quality: An Assessment of the Potency of Injectable Uterotonic Drugs Purchased by Simulated Clients in Three Districts in Ghana.” BMJ Open 2 (3): 1-7.
39. Stanton, C., D. Nand, A. Koski, E. Mirzabagi, S. Brooke, B. Grady, and L. C. Mullany. 2014. “Accessibility and Potency of Uterotonic Drugs Purchased by Simulated Clients in Four Districts in India.” BMC Pregnancy Childbirth 14 (1): 386.
40. Torstensson, David, and Meir Pugatch. 2010. “Keeping Medicines Safe -A Study of the Regulations Guiding the Approval of Medicines in Emerging Markets.” Stockholm Network. Accessed June 1, 2014. http://www.stockholm-network.org/Publications/5.
41. UNDP (United Nations Development Programme). 2009. “Human Development Report 2009.Overcoming Barriers: Human Mobility and Development.” Accessed August 12, 2014. http://hdr.undp.org/sites/default/files/reports/269/hdr 2009encomplete.pdf.
42. United Nations. 2005-10. “World Population Perspectives.” http://esa.un.org/unpd/wpp/.
43. United Nations. 2010. “World Urbanization Prospects, the 2009 Revision.” March. Accessed March 2015. http://esa.un.org/unpd/wup/FinalReport/WUP2014-Report.pdf.
44. USP (United States Pharmacopeial Convention). 2013. “Post-Market Quality Surveillance Project: Maternal Healthcare Products (Oxytocin and Ergometrine) on the Ghanaian Market.” Accessed August 12, 2014. http://www.usp.org/sites/default/files/usppdf/EN/PQM/ghana-mchmqmreportfinal-mar272013rdct.pdf.
45. World Justice Project. 2010, 2012, 2014. “Rule of Law Index.” http://worldjusticeproject.org/publications.